Please login to the form below
metastatic hormone-sensitive prostate cancer
This page shows the latest metastatic hormone-sensitive prostate cancer news and features for those working in and with pharma, biotech and healthcare.
Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
Pfizer and Astellas have reported positive top line results from a phase 3 trial of their androgen receptor signalling inhibitor, Xtandi (enzalutamide), in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with ... The medicine is already a
Latest news
-
Bayer’s Nubeqa receives MHRA approval to treat metastatic prostate cancer
hormone-sensitive prostate cancer (mHSPC). ... Around 9, 000 patients go on to develop metastatic prostate cancer.
-
Janssen’s Erleada combination accepted in Scotland for prostate cancer
been accepted by the Scottish Medicines Consortium (SMC) as an option for treating adults with metastatic hormone-sensitive prostate cancer (mHSPC) within NHS Scotland. ... It is indicated for use in the UK for the treatment of patients with
-
Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
Bayer’s Nubeqa (darolutamide) tablets, in combination with docetaxel, have been approved by the US Food and Drug Administration (FDA) to treat adults with metastatic hormone-sensitive prostate cancer (mHSPC). ... Despite these treatments, a large
-
Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer
In February, Janssen revealed additional results for Erleada, this time in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ... In the EU, Erleada is approved for the treatment of
-
Janssen’s Erleada improves survival in certain advanced prostate cancer patients
The TITAN study evaluated Erleada (apalutamide) plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to placebo plus ADT. ... Janssen is committed to uncovering new solutions for patients with prostate cancer as, until
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- FDA external report recommends actions to address US opioid crisis
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Inizio appoints Stefanie Christmas as global head of DE&I
- Rare diseases: not so rare after all
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
